What Makes Amentum Holdings (AMTM) an Attractive Bet?
In its first quarter 2025 investor letter, Frontier Small Cap Growth Fund highlighted stocks such as Amentum Holdings, Inc. (NYSE:AMTM). Amentum Holdings, Inc. (NYSE:AMTM) offers engineering and technology solutions to the U.S. and allied government agencies. The one-month return of Amentum Holdings, Inc. (NYSE:AMTM) was 8.47%, and YTD its shares gained 15.07% of their value. On July 7, 2025, Amentum Holdings, Inc. (NYSE:AMTM) stock closed at $24.20 per share, with a market capitalization of $5.888 billion.
Frontier Small Cap Growth Fund stated the following regarding Amentum Holdings, Inc. (NYSE:AMTM) in its first quarter 2025 investor letter:
"The market volatility has created several opportunities to invest in companies at prices we find attractive, and thus we have initiated new positions in a variety of industries. Examples include CACI International Inc, Amentum Holdings, Inc. (NYSE:AMTM), Essential Properties Realty Trust, Inc., and DigitalOcean Holdings, Inc. CACI and Amentum both provide essential services to the Department of Defense and other governmental agencies. These companies recently saw a dramatic decline in their stock prices as investors became concerned that the newly formed Department of Government Efficiency (DOGE) would recommend cuts across all government areas. While pruning inefficient spending is likely, we believe that the mission critical nature of the projects on which CACI and Amentum work, together with the considerable cost the government would incur to bring this work in-house, are testaments to the value these companies provide. While some projects may be delayed, increased spending on defense and digital infrastructure should enable these companies to grow earnings during the next few years."
A diverse team of professionals working together to deliver sophisticated engineering solutions.
Amentum Holdings, Inc. (NYSE:AMTM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held Amentum Holdings, Inc. (NYSE:AMTM) at the end of the first quarter, compared to 29 in the previous quarter. While we acknowledge the potential of Amentum Holdings, Inc. (NYSE:AMTM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered Amentum Holdings, Inc. (NYSE:AMTM) and shared the list of best new stocks to buy. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of AMTM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche
The United States Personalized Medicine Market is projected to soar to US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, experiencing a CAGR of 6.82% from 2025 to 2033. Key growth drivers include advances in next-generation sequencing, rising demand for customized treatments, and government policy support. The integration of technologies like AI and machine learning is enhancing precision in diagnostics and treatment, revolutionizing personalized healthcare. Market challenges include high development costs and limited clinical standardization. Major players such as Abbott Laboratories and Illumina, Inc., are at the forefront of this transformative sector. U.S. Personalized Medicine Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Personalized Medicine Market - Genomic Trends & Forecast 2025-2033" report has been added to States Personalized Medicine Market is expected to reach US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, with a CAGR of 6.82% from 2025 to 2033 Advances in next-generation sequencing, rising patient demand for customized treatments, the prevalence of chronic diseases, encouraging government policies, and rising investments in biotechnology and digital health technologies are some of the major factors propelling the US personalized medicine market. Innovations in digital health, biotechnology, and genomics are propelling the revolutionary expansion of the customized medicine sector in the United States. The goal of personalized medicine is to adjust medical care to each patient's unique traits, such as their environment, lifestyle, and genetic composition. With this strategy, healthcare is moving away from the conventional "one-size-fits-all" paradigm and toward more accurate, predictive, and preventative treatment. Healthcare providers and pharmaceutical firms are investing more in research and development to provide treatments with better efficacy and fewer side effects as a result of the increased emphasis on customized incorporation of advanced technologies like artificial intelligence, machine learning, and next-generation sequencing into clinical and research settings is a major factor driving this industry. Clinicians can use these technologies to find biomarkers, genetic mutations, and other molecular signs that help with diagnostic and treatment choices. The capacity to match patients with tailored therapies is also being improved by the growing availability of companion diagnostics, especially in intricate domains like neurology and cancer. Because of this, customized medicine is changing clinical procedures, encouraging early intervention, and facilitating better illness management in a variety of therapeutic domains. The industry is also being driven ahead by government assistance, changing regulations, and cooperation between the public and private sectors. The infrastructure required for the widespread adoption of customized healthcare is being built in part by initiatives to gather and analyze a variety of patient data. Additionally, healthcare practitioners are being prompted to embrace more patient-centric methods due to rising patient awareness and desire for customized treatment alternatives. The United States is now positioned as a worldwide leader in customized medicine, and these advancements are fostering an atmosphere that is conducive to innovation. Cost, data privacy, and accessibility issues still exist as the sector develops, but sustained cooperation and advancements in technology could help to overcome these obstacles and spur further Factors Driving the United States Personalized Medicine Market Growth Advancements in Genomic and Molecular TechnologiesAdvances in molecular diagnostics, bioinformatics, and genome sequencing are greatly speeding up the use of customized medicine in the United States. These technologies make it possible to identify biomarkers and genetic variants that aid in customizing treatment regimens for each patient. Patient genomes may now be analyzed more quickly and affordably thanks to next-generation sequencing and other high-throughput technologies. This reduces trial-and-error in therapy selection, which improves treatment results in addition to improving diagnostic accuracy. These technologies are being incorporated into standard clinical practice as they become more affordable and available, especially in areas like pharmacogenomics, uncommon illnesses, and cancer. This technical advancement is still a significant driver of market expansion for biopharmaceutical businesses, hospitals, and research Demand for Targeted TherapiesMore and more patients and medical professionals are looking for treatments that are tailored to each patient's unique health profile, especially for chronic or complicated illnesses like diabetes, autoimmune diseases, and cancer. A move toward more accurate, focused therapy has resulted from the unintended side effects and variable results of traditional treatments. In order to improve efficacy and safety, personalized medicine uses genetic and molecular data to anticipate a patient's response to certain therapies. Pharmaceutical firms are investing more in biologics and companion diagnostics as a result of the desire for customized treatment, which is also having an impact on drug development pipelines. The need for customized medicine is rising in all healthcare settings as more people become aware of the advantages of tailored Regulatory and Policy EnvironmentThe United States' regulatory environment has shifted in favor of customized medicine, fostering innovation and expediting the approval of focused treatments. Frameworks and criteria for assessing companion diagnostics and precision medicines have been created by organizations like the U.S. Food and Drug Administration (FDA). A solid basis for market expansion has been established by initiatives including national genome projects, public-private collaborations, and federal support for precision medicine research. The goal of these initiatives is to hasten the shift from conventional to individualized care models. Furthermore, the financial feasibility of customized medicine solutions is being further enhanced by continuous improvements in healthcare payment systems that are gradually opening up individualized therapies to a wider in the United States Personalized Medicine Market High Costs of Development and TreatmentCosts associated with personalized medicine are high, especially when it comes to research, genetic testing, and medication development. A substantial investment in clinical trials, genetic research, and regulatory approval procedures is necessary to develop customized treatments. Furthermore, many patients cannot afford the exorbitant cost of many customized treatments, particularly those involving biologics or cell and gene therapies. Additionally, the expense of sophisticated sequencing technology and companion diagnostics may prevent widespread usage in routine clinical settings. Both individuals and healthcare providers have financial difficulties as a result of these high costs, which frequently lead to inadequate insurance coverage. The high cost of customized medicine continues to be a significant obstacle to its wider adoption throughout the American healthcare system until more scalable and reasonably priced models are Standardization and Integration in Clinical PracticePersonalized medicine has not yet been completely incorporated into standard clinical care, despite its potential. The lack of uniformity in the interpretation and use of genomic data is a significant obstacle. Complex genetic information can be difficult for healthcare professionals to comprehend and use, especially in basic care settings. Furthermore, a large number of electronic health records (EHRs) lack the necessary tools for effectively managing or integrating genetic data. The lack of qualified experts, such as precision medicine specialists and genetic counselors, is another issue impeding broad adoption. The actual implementation of customized medicine in healthcare facilities is still uneven in the absence of uniform procedures, training, and smooth technology integration. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Abbott Laboratories GE Healthcare, Inc. Aadi Bioscience, Inc. Illumina, Inc. QIAGEN Eli Lilly and Company Takeda Pharmaceutical Company Ltd AbbVie Inc. F. Hoffmann-La Roche Ltd. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $169.56 Billion Forecasted Market Value (USD) by 2033 $307.04 Billion Compound Annual Growth Rate 6.8% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. United States Personalized Medicine Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product6.2 By Application6.3 By End Users7. Product7.1 Personalized Medicine Therapeutics7.2 Personalized Medicine Diagnostics7.3 Personalized Medical Care7.4 Personalized Nutrition and Wellness8. Application8.1 Oncology8.2 Infectious disease8.3 Neurology or Psychiatry8.4 Cardiovascular8.5 Others9. End Users9.1 Hospitals9.2 Diagnostic Centers9.3 Research & Academic Institutes9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Personalized Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, affecting over 3.4 million Americans, and advancements in drug development. Key players like Eisai, UCB, and Lundbeck emphasize second and third-generation AEDs offering improved safety and efficacy. Despite challenges like high treatment costs and regulatory hurdles, the market benefits from supportive FDA policies. Segmentation includes first, second, and third-generation drugs across various seizures and distribution channels. U.S. Epilepsy Drugs Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2025-2033" report has been added to States Epilepsy Drugs Market is expected to reach US$ 3.45 billion by 2033 from US$ 2.36 billion in 2024, with a CAGR of 4.31% from 2025 to 2033 In order to satisfy shifting customer needs, firms are being prompted by this transition to innovate and diversify their product lines. All things considered, the market for French-flavored milk is expected to grow further due to innovation, custom, and customer preferences. The market for epilepsy medications in the United States is a vibrant area of the larger neurology therapeutics business, with a wide range of antiepileptic medications (AEDs) that target different kinds of seizures. North America accounted for the greatest portion of the worldwide market for epilepsy medications in 2024, with the United States leading the way in terms of market size and revenue production. Due to their enhanced safety profiles and effectiveness, second-generation AEDs are growing at the quickest rate in the market, which is divided into first, second, and third-generation AEDs. The high demand for efficient treatment solutions is shown by the estimated 1.2% prevalence of epilepsy in the United prevalence of epilepsy has increased in the U.S. population. The seizures Foundation estimates that more than 3.4 million Americans suffer from seizures. Furthermore, 1 in 26 Americans are predicted to receive a diagnosis of epilepsy at some point in their lives, with over 150,000 receiving a diagnosis each year. New developments in medication development have accelerated the market's growth even further. The FDA's 2022 approval of ganaxolone (Ztalmy) for the treatment of seizures linked to CDKL5 deficient condition was a noteworthy milestone that provided a new therapeutic option for a patient population that had previously been underserved. Furthermore, the growing investment in specialist epilepsy medicines is demonstrated by Lundbeck's $2.6 billion acquisition of Longboard Pharmaceuticals in 2024, which was intended to develop bexicaserin for the treatment of developmental and epileptic encephalopathies. These advancements are in line with the demand for treatments that target complicated and uncommon epilepsy disorders as well as the increased emphasis on customized Factors Driving the United States Epilepsy Drugs Market Growth Increasing Prevalence of EpilepsyOne of the main factors propelling market growth is the increasing prevalence of epilepsy in the United States. It affects around 2.9 million individuals who are 18 years of age or older, with a significant incidence in youngsters. The need for efficient anti-epileptic medications (AEDs) is increased by this expanding patient base. Certain demographics, such as those from minority racial and ethnic groups and those with lower educational attainment, are more likely to have the syndrome. As more people look for medical intervention and treatment alternatives, the market is growing as a result of growing awareness and diagnosis of epilepsy. In order to satisfy the needs of a varied patient population, this trend emphasizes the necessity of ongoing innovation and accessibility in the creation and distribution of in Drug DevelopmentSecond and third-generation anti-epileptic medications (AEDs), which have better effectiveness and safety profiles, have been introduced as a result of ongoing research and development efforts. These more recent drugs aim to overcome the drawbacks of previous therapies by improving seizure control while reducing adverse effects. These developments not only improve patient outcomes but also provide medical professionals more treatment alternatives. The dedication to meeting the unmet requirements of the epilepsy community is seen in the ongoing pipeline of new AEDs, which propels market Regulatory EnvironmentFaster access to new medicines is made possible by the U.S. Food and Drug Administration's (FDA) accelerated approval of innovative anti-epileptic medications (AEDs). Pharmaceutical firms are encouraged to invest in the discovery of novel medicines by this regulatory assistance. Furthermore, programs like the Epilepsy Foundation's #RemoveTheFilter and National Epilepsy Awareness Month have raised public awareness and decreased stigma, which has encouraged more people to seek treatment. Because of these initiatives, the patient population is more informed, which increases the likelihood of diagnoses and treatment compliance. The market for epilepsy medications is expected to develop in a favorable environment because to a mix of supportive regulatory frameworks and increased public in the United States Epilepsy Drugs Market High Treatment Costs and Affordability IssuesAccess to therapy is severely hampered by the rising costs of antiepileptic medications (AEDs) in the US. For example, generic drugs are frequently less expensive than name-brand ones, such as Fycompa and Aptiom, which may cost thousands of dollars a month. Generics are not always readily available, and some more recent AEDs do not have generic counterparts, which keeps their prices high. Furthermore, insurance coverage might vary; Medicare seniors are frequently not eligible for co-pay assistance programs, and other plans have hefty deductibles or co-pays. These monetary difficulties may cause patients to stop taking their medications, which raises the risk of seizures and related problems. In order to provide fair access to efficient epilepsy therapies, it is imperative that these economic concerns be Hurdles and Market Entry DelaysNew antiepileptic medications (AEDs) must pass rigorous regulatory criteria enforced by the U.S. Food and Drug Administration (FDA), which include thorough documentation and lengthy clinical studies. For pharmaceutical firms, this stringent procedure may raise development costs and postpone the release of new medications. Furthermore, generic versions of important AEDs are introduced when their patents expire; although they are less expensive, they might not always satisfy the unique demands of every patient. People who need specialized care may have fewer alternatives due to these market factors. Additionally, market access and the profitability of AED development initiatives may be hampered by the drawn-out and expensive approval procedures linked to regulatory obstacles. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Eisai Co., Ltd. UCB Inc. H. Lundbeck A/S GW Pharmaceuticals Plc. Abbott Laboratories Alkem Laboratories Limited Bausch Health Companies Inc. GSK plc Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $2.36 Billion Forecasted Market Value (USD) by 2033 $3.45 Billion Compound Annual Growth Rate 4.3% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Exploring the Disease - Background and Key Insights5.1 Introduction5.2 Causes5.3 Classification of Epilepsies5.3.1 West Syndrome5.3.2 Dravet syndrome5.3.3 Lennox-Gastaut syndrome5.3.4 Landau-Kleffner syndrome5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)5.3.6 CDKL5 deficiency disorder (CDD)5.4 Risk Factors5.5 Pathophysiology5.6 Diagnosis5.6.1 Diagnostic Guidelines5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)5.6.1.3 The French National Authority for Health (HAS): 20205.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)5.7 Treatment5.7.1 Antiepileptic Medications (AEDs)5.7.2 Receptor Blockers5.7.3 Others5.7.4 Diet Therapy5.7.5 Surgery5.7.5.1 Phase I Evaluation (Noninvasive Tests)5.7.5.2 Phase II Evaluation (Invasive Mon)5.7.6 Treatment Algorithm for Medical Condition5.7.7 Treatment Guidelines5.7.7.1 American Epilepsy Society5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines5.7.7.4 NICE Guidelines: (2022)5.7.8 Living and Coping with Epilepsy6. United States Epilepsy Drugs Market6.1 Historical Market Trends6.2 Market Forecast7. Market Share Analysis7.1 By Drugs Category7.2 By Seizure types7.3 By Distribution Channels8. Drugs Category8.1 First Generation Drugs8.2 Second Generation Drugs8.3 Third Generation Drugs9. Seizure Types9.1 Focal Seizures9.2 Generalized Seizures9.3 Non-Epileptic Seizures10. Distribution Channels10.1 Hospital Pharmacies10.2 Drug Stores and Retail Pharmacies10.3 Online Providers11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Analysis of Marketed Medications/Drugs13.1 Key Players13.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals13.2.1 Description of Drugs13.2.2 Regulatory Milestones13.2.3 Clinical Development Process13.2.4 Safety and Efficacy13.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical13.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku13.5 NAYZILAM (midazolam) nasal spray - UCB Pharma13.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma13.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion13.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma13.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical13.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals13.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo14. Analysis of Emerging Drugs14.1 Key Cross Competition14.2 XEN1101 - Xenon Pharmaceuticals14.2.1 Description of Drug14.2.2 Clinical Research & Development14.2.3 Safety and efficacy14.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)14.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics14.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)14.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences14.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals14.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals14.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals15. Regulations and Reimbursement Policies16. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Epilepsy Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
The Next Generation of Dividend Kings: 3 Stocks to Watch
Key Points Only 4% of companies in the S&P 500 have delivered dividend growth on par with ExxonMobil. NNN REIT has the third-longest dividend growth streak in the REIT sector. Medtronic is on the cusp of joining this elite group of dividend stocks. 10 stocks we like better than ExxonMobil › Dividend Kings are the most durable dividend stocks, having increased their payouts annually for at least 50 consecutive years. This resilience is impressive, as they've weathered at least seven recessions in that time. The list of current Dividend Kings is short, with only 55 companies. More companies should join this group as they reach the milestone in the coming years. Here are three likely future Dividend Kings. 1. ExxonMobil ExxonMobil (NYSE: XOM) is steadily marching toward Dividend King status. The oil giant has now increased its dividend for 42 straight years, the longest current streak in the oil patch. Only 4% of companies in the S&P 500 (SNPINDEX: ^GSPC) have delivered dividend growth of 42 or more years. The energy company has put itself in a strong position to continue increasing its dividend. ExxonMobil's plan to 2030 aims to deliver the growth potential of $20 billion in earnings and $30 billion in cash flow by the dawn of the next decade. That has it on track to deliver compound annual growth rates of 10% for earnings and 8% for its cash flow over the next five years. Exxon aims to deliver this robust growth by investing $140 billion into higher-return major capital projects and its Permian Basin development program. It also expects to achieve another $7 billion in structural cost savings by 2030, compared to the third quarter of last year. Exxon is also building the energy company of the future by investing in several lower-carbon energy technologies, including hydrogen, carbon capture and sequestration, and lithium. These and other new businesses have the potential to add $3 billion to its earnings by 2030 and $13 billion by 2040. Combine all this with Exxon's fortress financial profile, and the oil giant seems destined to eventually earn the crown of Dividend King. 2. NNN REIT NNN REIT (NYSE: NNN) reached an important milestone last year when the real estate investment trust (REIT) delivered its 35th consecutive dividend increase. Only two other REITs and fewer than 80 publicly traded companies have reached that level. The REIT has since extended its streak to 36 straight years. The landlord has a very simple business model: It invests in single-tenant net leased properties. It acquires properties secured by long-term net leases (initial terms of 10 to 20 years) in prime locations within strong markets. These properties produce very reliable rental income. NNN REIT establishes relationships with expanding retailers, which steadily provide it with new investment opportunities. It typically acquires properties via sale-leaseback transactions. These relationship-based transactions provide clients with capital to continue expanding their retail footprints, which ultimately presents the REIT with new investment opportunities. NNN REIT maintains a conservative financial profile, which allows it to continue expanding its portfolio (and dividend) throughout the economic cycle. 3. Medtronic Medtronic (NYSE: MDT) is close to earning Dividend King status, with 48 straight years of dividend growth. The medical device maker is well-positioned to continue raising its payout. The healthcare company plans to separate its diabetes business over the next 18 months. It ideally plans to complete an initial public offering of the unit and a subsequent split-off of the business. This strategy will allow it to focus all its attention on its growing cardiovascular, neuroscience, and medical-surgical units. Those three markets are large and growing at a mid-to-high single-digit annual rate. Medtronic aims to capture a larger share of these expanding markets by continuing to invest heavily in research and development to launch new and improved products. It also has the balance sheet strength to make acquisitions as the right opportunities arise. These growth investments should increase its cash flow, enabling Medtronic to ascend to the next level of dividend royalty. Three likely future kings ExxonMobil, NNN REIT, and Medtronic are all well on their way to eventually becoming Dividend Kings. They have the financial strength and visible earnings growth potential to continue increasing their dividends for years to come. All this means they're ideal stocks to buy for those seeking durable, steadily rising dividend income. Should you invest $1,000 in ExxonMobil right now? Before you buy stock in ExxonMobil, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ExxonMobil wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Matt DiLallo has positions in Medtronic. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. The Next Generation of Dividend Kings: 3 Stocks to Watch was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
